The patient testimonial in the Jeuveau reel ran 38 seconds. Risk information came after it, behind a tagline held for about four seconds on a black screen, and that ordering is one of the reasons the Food and Drug Administration told Evolus on September 28, 2026 that the post was false or misleading. For anyone working on med spa social media compliance, the five-page letter is the most specific public description we have read of what a federal reviewer sees when watching an aesthetics reel.

It is one of two documents worth an hour of an owner's time. The other is the Federal Trade Commission's rule on consumer reviews and testimonials, 16 CFR Part 465, which took effect on October 21, 2024 and covers the kind of review request a practice sends after a visit.

Neither document is about med spas. FDA's letter went to a manufacturer and makes no finding about any practice, and the FTC rule applies to businesses generally. What follows about practices is our reading, and it is general information, not legal advice.

The four things FDA objected to

We covered the letter in detail in our news report. For a practice's content calendar, the objections sort into four types.

First, magnitude. The patient said she was excited about "getting rid of my lines" and that the line between her eyebrows "is gone." Jeuveau's approved indication is for "temporary improvement" in the appearance of moderate to severe glabellar lines, and FDA said claims of lines being "gone" or of "complete" results were not supported.

Second, speed. The caption read "Lines today. Blurred in as little as 2 days." According to the letter, the main efficacy measure in the studies was taken at Day 30, and the Day 2 timepoint was an exploratory endpoint with a lower threshold for response. Putting the two side by side, FDA wrote, "conflates the measures of response."

Third, treating a prescription drug like makeup. The caption said Evolus was "blurring the lines between what's found in your beauty bag and what happens in the treatment room," with syringe and lipstick icons. FDA said that likens an injectable prescription product to an everyday beauty product and minimizes the risks of a drug with a boxed warning.

And fourth, where the risk information sat. It appeared only at the end of the reel, and in the caption a viewer had to scroll past more benefit claims to reach it. By the letter's timings, that is roughly 42 seconds before any risk information (38 seconds of testimonial plus about four of tagline).

Two details should give a marketer pause. FDA accepted that the testimonial "may be an accurate reflection of this patient's own experience" and still said it did not support the suggestion that all patients would respond the same way. An on-screen "Individual results may vary" did not fix it either.

Reposting the manufacturer's content

Does a practice that reshares a brand's reel carry the brand's problem? The letter does not say. It asks Evolus to list its own promotional communications with similar claims and explain its plan to discontinue them.

Our view is a practical one. If the manufacturer pulls or edits a post after a letter like this, a copy sitting on your grid is now a version the company itself has walked away from. Keep a simple log of brand content you have reshared, with dates, so someone can find and remove it in ten minutes. A practice's own advertising also answers to the FTC Act and to whatever advertising rules the state boards that license its providers enforce. Those differ by state, and we did not review any state's rule for this piece.

Reviews: what the FTC rule actually bars

Section 465.4 makes it a violation for a business to provide compensation or other incentives "in exchange for, or conditioned expressly or by implication on," reviews expressing a particular sentiment, positive or negative.

"By implication" does a lot of work. FTC staff's question-and-answer page on the rule, which describes itself as guidance that is not definitive and offers no safe harbor, gives two examples of wording that implies a review must be positive. One is "Tell us how much you loved your visit to John's Steakhouse and get a $5 coupon."

Here is an illustration with made-up numbers. Say a practice sees 200 patients a month, emails each one a $25 credit offer for a review, and 10% respond. That is 20 reviews and $500 a month in credits (20 times $25). A credit like that comes out of the same margin as member pricing. Whether it is a lawful marketing cost turns on one sentence in the email.

Wording of the offerHow the FTC material treats it
"Leave us a 5-star review and take $25 off your next visit"Staff guidance: paying incentives for 5-star reviews violates section 465.4, even with a disclosure
"Tell us how much you loved your visit and take $25 off"Staff guidance treats this pattern as implying the review must be positive
"Review us, good or bad, and take $25 off"Not prohibited by the rule, per staff guidance, but failing to disclose the incentive could violate the FTC Act

I'd rather not pay for reviews at all. The third version is the only one the guidance leaves open, and it still depends on a disclosure the practice has to get each reviewer to make.

Staff, family and the owner's own account

Section 465.5 covers insiders. An officer or manager who writes a review or testimonial about the business has to disclose the relationship clearly and conspicuously, unless, for a testimonial, the relationship is otherwise clear to the audience. Staff guidance says context can do that job, such as a video showing the person "wearing a company uniform." An injector in scrubs in the treatment room is probably fine on that reading. A front-desk manager's five-star Google review under a personal account is not, without a disclosure.

A manager who asks employees to get their relatives to post reviews is covered too, under 465.5(c), when those reviews appear without a disclosure and the manager did not tell people to make one.

Three other parts of the rule matter to a small practice. Section 465.2 bars fake reviews and testimonials. Section 465.7 bars using groundless legal threats or intimidation to get a review removed, which is worth remembering before anyone drafts an angry reply to a one-star post. And 465.8 bars buying followers, views or likes that the buyer knew or should have known were fake, where they materially misrepresent the business's influence for a commercial purpose. The FTC's guidance page says the rule lets courts impose civil penalties for knowing violations.

One gap. Asking only your happiest patients for reviews is not specifically prohibited by the rule, according to the staff guidance, which adds that the practice "could violate the FTC Act."

What gets engagement anyway

There is a commercial argument for toning down the sales content. Guidepoint Qsight's January 2026 industry deck ranked Instagram post categories by average engagement in 2025, using a weighted engagement score. Staff spotlight and culture posts ranked first. Testimonial, sales promotion and personal selling sat at the bottom of the list, just above a catch-all "other" bar, and compliance and safety posts ranked fourth from the top.

Qsight is a commercial data vendor and the slide gives no method beyond the score's name, so take the ranking as one vendor's read. But it points the same way as the two documents above. The testimonial and promotion content they deal with sits near the bottom of that chart.

Sources